Based on this observation, a standard chemotherapy approach (IC or HMAs) alone is a rational choice of therapy in AML patients with non-detectable or marginally detectable bone marrow BCL-2 protein expression. The gene discussed is BCL2; the disease is acute myeloid leukemia.